FDA Approves Baxter's Hemophilia B Drug Rixubis for Pediatric Use

Sunday, September 28, 2014

Source: BioSpectrum Asia

Baxter International has received the FDA's approval to market Rixubis, or coagulation factor IX (recombinant), for the treatment of children with hemophilia B. The drug was approved for use in routine prophylaxis, perioperative management and control of bleeding episodes.

View All News »